1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with phenyl acetate in 11 studies
| Studies (1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid) | Trials (1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid) | Recent Studies (post-2010) (1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid) | Studies (phenyl acetate) | Trials (phenyl acetate) | Recent Studies (post-2010) (phenyl acetate) |
|---|---|---|---|---|---|
| 792 | 16 | 476 | 41,232 | 1,558 | 8,330 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Angelovski, G; Logothetis, NK; Mamedov, I; Parac-Vogt, TN | 1 |
| Kjaer, A; Madsen, J; Persson, M; Ploug, M; Østergaard, S | 1 |
| Altai, M; Braun, A; Garske, U; Karlström, AE; Malmberg, J; Orlova, A; Perols, A; Sandström, M; Tolmachev, V; Varasteh, Z | 1 |
| Baidoo, KE; Brechbiel, MW; Kim, YS; Milenic, DE; Nwe, K; Satz, S | 1 |
| Altai, M; Eriksson Karlström, A; Orlova, A; Rosik, D; Selvaraju, RK; Strand, J; Tolmachev, V | 1 |
| Asti, M; Atti, G; Bergmann, R; Brennauer, A; Capponi, PC; Erba, PA; Iori, M; Martin, R; Müller, M; Rubagotti, S; Versari, A | 1 |
| Blower, PJ; Boerman, OC; Burnet, J; Cooper, MS; Foster, JM; Hudson, C; Joosten, L; Kolenc-Peitl, PK; Laverman, P; Leyton, J; Mather, SJ; Oyen, WJ; Roosenburg, S; Sosabowski, JK | 1 |
| Azhdarinia, A; Ghosh, SC; Gore, K; Harvey, BR; Pinkston, KL; Robinson, H; Sevick-Muraca, EM; Wilganowski, N | 1 |
| Al-Shoukr, F; Ben Azzouna, R; Guilloteau, D; Le Guludec, D; Leygnac, S; Rouzet, F | 1 |
| Böhmová, Z; Hermann, P; Holá, K; Kotek, J; Kubíček, V; Procházková, S | 1 |
| Battan, S; Bracke, A; De Loose, J; De Meester, I; Moon, ES; Rösch, F; Van der Veken, P; Van Rymenant, Y | 1 |
11 other study(ies) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and phenyl acetate
| Article | Year |
|---|---|
Synthesis and characterization of dinuclear heterometallic lanthanide complexes exhibiting MRI and luminescence response.
Topics: Acetates; Chelating Agents; Contrast Media; Coordination Complexes; Europium; Gadolinium; Heterocyclic Compounds, 1-Ring; Lanthanoid Series Elements; Ligands; Magnetic Resonance Imaging; Spectrometry, Fluorescence; Terbium | 2010 |
68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Topics: Acetates; Amides; Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Chelating Agents; Drug Stability; Female; Gallium; Gallium Radioisotopes; Glioma; Heterocyclic Compounds, 1-Ring; Humans; Mice; Neoplasm Invasiveness; Peptides; Positron-Emission Tomography; Protein Binding; Receptors, Urokinase Plasminogen Activator | 2012 |
Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
Topics: Acetates; Amino Acid Sequence; Animals; Antibodies, Monoclonal; Binding Sites; Cell Line, Tumor; Cell Transformation, Neoplastic; Chelating Agents; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Isotope Labeling; Male; Mice; Molecular Imaging; Molecular Sequence Data; Prostatic Neoplasms; Receptor, ErbB-2; Substrate Specificity | 2012 |
Synthesis and characterization of αvβ₃-targeting peptidomimetic chelate conjugates for PET and SPECT imaging.
Topics: Acetates; Chelating Agents; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Integrin alphaVbeta3; Lead Radioisotopes; Peptidomimetics; Positron-Emission Tomography; Radioimmunoassay; Tomography, Emission-Computed, Single-Photon | 2012 |
Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA.
Topics: Acetates; Animals; Cell Line, Tumor; Cells; Chelating Agents; Female; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Organometallic Compounds; Receptor, ErbB-2; Tissue Distribution | 2013 |
Influence of different chelators on the radiochemical properties of a 68-Gallium labelled bombesin analogue.
Topics: Acetates; Amino Acid Sequence; Bombesin; Chelating Agents; Drug Stability; Gallium Radioisotopes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Radiochemistry | 2014 |
PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.
Topics: Acetates; Animals; Cell Line, Tumor; Chelating Agents; Copper Radioisotopes; Female; Gallium Radioisotopes; Gastrins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Inhibitory Concentration 50; Mice; Mice, SCID; Multimodal Imaging; Neoplasm Transplantation; Peptides; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, Cholecystokinin B; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2014 |
Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
Topics: Acetates; Animals; Antibodies, Monoclonal; Biological Transport; Cell Line, Tumor; Chelating Agents; Copper Radioisotopes; Drug Stability; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Male; Mice; Tissue Distribution | 2015 |
68Ga 'vacuum elution approach' for direct radiolabelling of DOTA-conjugated and NODAGA-conjugated peptides.
Topics: Acetates; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Occupational Exposure; Oligopeptides; Positron-Emission Tomography; Quality Control; Radiation Exposure; Radiometry; Radiopharmaceuticals; Vacuum | 2017 |
DOTA analogues with a phosphinate-iminodiacetate pendant arm: modification of the complex formation rate with a strongly chelating pendant.
Topics: Acetates; Chelating Agents; Copper; Heterocyclic Compounds, 1-Ring; Ligands; Models, Molecular; Molecular Conformation; Organometallic Compounds; Phosphines | 2017 |
In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA
Topics: Acetates; Azepines; Endopeptidases; Fibroblasts; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Membrane Proteins; Positron Emission Tomography Computed Tomography; Quinine; Radioisotopes; Radiopharmaceuticals; Scandium; Serine Endopeptidases | 2021 |